WENHUI CAI: Open Payments
NPI 1679657910 · TUCSON, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$9,205 in 39 payments from 12 companies in 2025. Trend: 2023 $9,657 · 2024 $680 · 2025 $9,205
Consulting: $6,888Travel & lodging: $1,169Food & beverage: $1,143Education: $5
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 15 | $8,611 |
| Janssen Pharmaceuticals, Inc | 7 | $128 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $102 |
| Janssen Scientific Affairs, LLC | 1 | $66 |
| E.R. Squibb & Sons, L.L.C. | 2 | $52 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| Alkermes, Inc. | 2 | $48 |
| Teva Pharmaceuticals USA, Inc. | 2 | $46 |
| Biogen, Inc. | 1 | $28 |
| ABBVIE INC. | 1 | $28 |
Products named: INGREZZA, INVEGA SUSTENNA, CAPLYTA, COBENFY, AUSTEDO XR, REXULTI, ZURZUVAE, VRAYLAR.
Industry payments across AZ — which companies pay providers there.
